<DOC>
	<DOC>NCT02529579</DOC>
	<brief_summary>The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.</brief_summary>
	<brief_title>Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1. Advanced Pancreatic cancer patients with histological pathology confirmation 2. Both gender, aged 1870 yearold 3. Bone marrow functioned well 4. Renal function normal 5. Liver function normal 6. patients are voluntary, and willing to sign informed consent 7. expected lifetime was at least 3 months 1. With acute inflammation 2. Accompanied with primary malignant tumor other than pancreas 3. with autoimmune disease 4. using corticosteroid or other suppress immune hormone treatment 5. had transplant operation of vital organs 6. active hepatitis 7. HIV positive 8. dysfunction in blood coagulation 9. serious diseases in circulatory and respiratory systems 10. pregnancy or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>adoptive Cellular Immunotherapy</keyword>
	<keyword>patient safety</keyword>
	<keyword>therapeutic effect</keyword>
</DOC>